TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12560443

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 micro g/kg (single subcutaneous injection)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Filgrastim 5 micro g/kg (daily subcutaneous injections)
Number of subjects: 66
Study: 10364416

Group type: EXPERIMENTAL
Intervention: 1 set of arm-curl training (80% 1-RM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3 sets of arm-curl training (80% 1-RM)
Number of subjects: 8
Study: 8818089

Group type: EXPERIMENTAL
Intervention: Rice porridge feeding 5 hours 30 minutes before anesthesia induction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fasted group (control) allowed solid food until midnight before surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rice porridge feeding
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fasted group (control)
Number of subjects: 20
Study: 1441876

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 117
Study: 6588473

Group type: EXPERIMENTAL
Intervention: Norepinephrine, 0.4 micrograms/kg/min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Orciprenaline, 2 micrograms/kg/min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Phentolamine, 50 micrograms/kg/min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol, 10 micrograms/kg/min
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 44
Study: 31445316

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2.5 g/d for 45 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 40
Study: 30115598

Group type: EXPERIMENTAL
Intervention: Amisulpride (up to 800 mg/day) for 4 weeks
Number of subjects: 481

Group type: COMPARATOR
Intervention: Olanzapine (≤20 mg/day) for 6 weeks
Number of subjects: 481

Group type: COMPARATOR
Intervention: Amisulpride for 6 weeks
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Clozapine (≤900 mg/day) for 12 weeks
Number of subjects: 481
Study: 27103795

Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg
Number of subjects: 1017

Group type: COMPARATOR
Intervention: TIO 18 μg
Number of subjects: 1017
Study: 24568323

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medications for pain relief
Number of subjects: 50
Study: 22291116

Group type: EXPERIMENTAL
Intervention: NCPAP with heliox (80% helium and 20% oxygen)
Number of subjects: 51

Group type: COMPARATOR
Intervention: NCPAP with medical air (control group)
Number of subjects: 51
Study: 19896176

Group type: EXPERIMENTAL
Intervention: Immediate voltage escalation SWL
Number of subjects: 160

Group type: COMPARATOR
Intervention: Delayed voltage escalation SWL
Number of subjects: 160
Study: 17362372

Group type: EXPERIMENTAL
Intervention: Intergroup competition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intergroup competition
Number of subjects: 0
Study: 16278614

Group type: EXPERIMENTAL
Intervention: 0.9 mg of estradiol acetate (n = 79)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: 1 mg of micronized estradiol (n = 85)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens (n = 85)
Number of subjects: 249
Study: 12192282

Group type: EXPERIMENTAL
Intervention: I-123 MIBG imaging
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: I-123 BMIPP imaging
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise-induced stress perfusion imaging
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Myocardial biopsy
Number of subjects: 29
Study: 10205099

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg a day for 12 weeks (T12)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg a day for 16 weeks (T16)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Itraconazole 400 mg a day for 1 week in every 4 weeks for 12 weeks (I3)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Itraconazole 400 mg a day for 1 week in every 4 weeks for 16 weeks (I4)
Number of subjects: 496
Study: 7845310

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Interferon alfa (combined data)
Number of subjects: 62
Study: 1960382

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 31
Study: 7148742

Group type: EXPERIMENTAL
Intervention: 7-day diet records
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 3-day diet records
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 6-h recalls
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 24-h recalls
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Interviewer
Number of subjects: 107
Study: 31865785

Group type: EXPERIMENTAL
Intervention: Enalapril plus folic acid
Number of subjects: 19053

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 19053
Study: 30522343

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/d)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 28821597

Group type: EXPERIMENTAL
Intervention: e‐DCT (electronic discharge communication tool)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Usual care (traditional discharge communication)
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: e‐DCT
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1399
Study: 27631380

Group type: EXPERIMENTAL
Intervention: House Calls (HC) educational intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Individual Counseling (IC)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Group-Based (GB) intervention
Number of subjects: 152
Study: 24533792

Group type: EXPERIMENTAL
Intervention: Educational intervention (one-day intensive training, poster presentation, regular visits, reminder messages over 4 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 23018300

Group type: EXPERIMENTAL
Intervention: 6-row 3-D linear cutter (N group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard 4-row linear cutter (S group)
Number of subjects: 41
Study: 20308833

Group type: EXPERIMENTAL
Intervention: 10 mg gestrinone
Number of subjects: 998

Group type: COMPARATOR
Intervention: 10 mg mifepristone
Number of subjects: 998
Study: 17678655

Group type: EXPERIMENTAL
Intervention: Circuit class therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Individual physiotherapy sessions
Number of subjects: 68
Study: 15333619

Group type: EXPERIMENTAL
Intervention: Ad hoc imputation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal modelling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifying the modelling method for non-ignorable dropout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common imputation model in both groups
Number of subjects: 0
Study: 12230417

Group type: EXPERIMENTAL
Intervention: Current use of estrogen with progestin
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Current use of estrogen without progestin
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Hormone use (first 6 months)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Estrogen dose
Number of subjects: 726
Study: 10219357

Group type: EXPERIMENTAL
Intervention: Experimental telephone management educational program using a standardized patient (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback to the experimental group
Number of subjects: 0
Study: 7606199

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800 mg/m2/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 26
Study: 2114050

Group type: EXPERIMENTAL
Intervention: Home-made powder product (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ready-made sterile standard tube-feeding product: Salvimulsin MCT (group 2)
Number of subjects: 40
Study: 856022

Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0
Study: 31709910

Group type: EXPERIMENTAL
Intervention: SOLE MATES program (six face-to-face sessions over six weeks)
Number of subjects: 58
Study: 30366744

Group type: EXPERIMENTAL
Intervention: Intravenous morphine and haloperidol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intravenous morphine with normal saline (Control)
Number of subjects: 140
Study: 26096021

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 42
Study: 25936892

Group type: EXPERIMENTAL
Intervention: NAV method (electromagnetically-guided navigation system)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CT-guidance (standard computed tomography guidance)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: NAV method
Number of subjects: 54

Group type: COMPARATOR
Intervention: CT-guidance
Number of subjects: 54
Study: 23895088

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA, n = 57)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI, n = 61)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Ecologically-Based Family Therapy (EBFT, n = 61)
Number of subjects: 179
Study: 23108883

Group type: EXPERIMENTAL
Intervention: Ear melanoma with ulceration
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Nonear melanoma with ulceration
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Nonear melanoma with thickness
Number of subjects: 405
Study: 19734176

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, one inhalation twice daily)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/500 microg, one inhalation twice daily)
Number of subjects: 442
Study: 17552386

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's space injection with a mixture of 3 mL of 2% lidocaine with hyaluronidase and 3 mL of 0.5% bupivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no sub-Tenon's space injection)
Number of subjects: 46
Study: 15506554

Group type: EXPERIMENTAL
Intervention: 3.5 mL (26.25 mg) of 0.75% glucose-free ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4.5 mL (33.75 mg) of 0.75% glucose-free ropivacaine
Number of subjects: 40
Study: 11510013

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) induction at a dose of 1.5 mg/kg IV
Number of subjects: 71

Group type: COMPARATOR
Intervention: Methylprednisolone, 1,000 mg IV
Number of subjects: 71
Study: 9576460

Group type: EXPERIMENTAL
Intervention: Duodenal infusion of heparinized autologous blood
Number of subjects: 7

Group type: COMPARATOR
Intervention: Egg white (control)
Number of subjects: 7
Study: 8200260

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2a therapy
Number of subjects: 36
Study: 3499211

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside/cyclophosphamide pulses every eight weeks during continuation therapy
Number of subjects: 177

Group type: COMPARATOR
Intervention: No ara-C/cyclo pulses
Number of subjects: 177
Study: 30337597

Group type: EXPERIMENTAL
Intervention: 23‐valent PPV vaccination
Number of subjects: 2
Study: 26056191

Group type: EXPERIMENTAL
Intervention: 600 mg propafenone
Number of subjects: 12
Study: 25299236

Group type: EXPERIMENTAL
Intervention: Hepatitis A/Hepatitis B vaccinations
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Linkage to care for Hepatitis C positive individuals
Number of subjects: 489
Study: 23087298

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (two 5-min lower limb tourniquet occlusions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (un-inflated tourniquet)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 20192142

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 60
Study: 18547692

Group type: EXPERIMENTAL
Intervention: Allogenic acellular dermal matrix (ADM) graft during superficial or partial parotidectomy (n=64)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Superficial or partial parotidectomy alone (control group, n=104)
Number of subjects: 168
Study: 15849842

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol (100 mg once a day)
Number of subjects: 20
Study: 12585167

Group type: EXPERIMENTAL
Intervention: Conventional plus Salvia Injection (SI) intervention treated group (24 cases)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional steroid treated group (20 cases)
Number of subjects: 44
Study: 10368505

Group type: EXPERIMENTAL
Intervention: Tocolytic agents used in abruptio placentae group (95 women, 73%)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Tocolytic agents used in placenta previa group (78 patients, 72%)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Tocolytic agents (combined patients: 171)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (not treated with tocolytic agents)
Number of subjects: 236
Study: 7577279

Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 2040318

Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Heparin alone (Control)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined clinical scoring system
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Decrease of sigma-ST at 2 h post-treatment
Number of subjects: 103
Study: 6786146

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31060586

Group type: EXPERIMENTAL
Intervention: DNA fragments from Lactococcus lactis strain Plasma (LC‐Plasma) with varying CpG motif copy numbers and G + C contents.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAB strains with high pDCs stimulatory activity.
Number of subjects: 0
Study: 29022763

Group type: EXPERIMENTAL
Intervention: Training for healthcare providers
Number of subjects: 46546

Group type: COMPARATOR
Intervention: Doctors providing advice
Number of subjects: 46546

Group type: COMPARATOR
Intervention: Risk status of patients
Number of subjects: 46546
Study: 25943673

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation combined with a cooling vest (LFESCR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Active recovery combined with a cooling vest (ACTCR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-frequency electrical stimulation (LFES)
Number of subjects: 8
Study: 24252714

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Referral to community-based resources
Number of subjects: 306
Study: 22692704

Group type: EXPERIMENTAL
Intervention: AMG 386 at 10 mg/kg plus sorafenib 400 mg orally twice daily (arm A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: AMG 386 at 3 mg/kg plus sorafenib 400 mg orally twice daily (arm B)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo plus sorafenib 400 mg orally twice daily (arm C)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Open-label AMG 386 at 10 mg/kg plus sorafenib after disease progression (for patients in arm C)
Number of subjects: 152
Study: 18977820

Group type: EXPERIMENTAL
Intervention: L-dopa (acute challenge)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (acute challenge)
Number of subjects: 0
Study: 16971054

Group type: EXPERIMENTAL
Intervention: Usual care plus abstinence-based incentives (N=209)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care (N=206)
Number of subjects: 415
Study: 14674961

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 26
Study: 11503113

Group type: EXPERIMENTAL
Intervention: Titanium proximally porous-coated femoral component with hydroxyapatite-tricalcium phosphate coating
Number of subjects: 39

Group type: COMPARATOR
Intervention: Titanium proximally porous-coated femoral component without hydroxyapatite-tricalcium phosphate coating
Number of subjects: 39
Study: 9560874

Group type: EXPERIMENTAL
Intervention: Naltrexone (ReVia, DuPont, Wilmington, DE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8062610

Group type: EXPERIMENTAL
Intervention: Overnight urinary albumin excretion rate (AER) determined by radioimmunoassay
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Initial AER in the range of 53-76 micrograms/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Initial AER > or = 53 or > or = 80 micrograms/min
Number of subjects: 13
Study: 3068567

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28816582

Group type: EXPERIMENTAL
Intervention: Conductive education (CE) course followed by conventional practice
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional practice (waiting list group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional practice (both groups)
Number of subjects: 21
Study: 29953171

Group type: EXPERIMENTAL
Intervention: 1% clotrimazole powder (1% CP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: 1% clotrimazole cream (1% CC)
Number of subjects: 67
Study: 24045856

Group type: EXPERIMENTAL
Intervention: Danish return-to-work (RTW) program
Number of subjects: 3105

Group type: COMPARATOR
Intervention: Ordinary sickness benefit management (OSM)
Number of subjects: 3105
Study: 22691051

Group type: EXPERIMENTAL
Intervention: Elective Birth at 37 weeks (n=116)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard Care (n=119)
Number of subjects: 235
Study: 20130487

Group type: EXPERIMENTAL
Intervention: Visual estimation of blood loss with vital signs indicating instability (low blood pressure, high heart rate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual estimation of blood loss without specific vital signs
Number of subjects: 0
Study: 18494851

Group type: EXPERIMENTAL
Intervention: Group A (ETC inserted and fixed in the midline)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (ETC inserted along the angle of the mouth and fixed laterally)
Number of subjects: 30
Study: 15376818

Group type: EXPERIMENTAL
Intervention: CD‐ROM plus parent intervention
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: CD‐ROM only
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control
Number of subjects: 514
Study: 11137810

Group type: EXPERIMENTAL
Intervention: 3mg sodium nitroprusside in 10ml of 5% dextrose solution sprayed on the pedicle (Group I, n=42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Half of the sodium nitroprusside solution sprayed and half injected into the pedicle (Group II, n=44)
Number of subjects: 86
Study: 9919476

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study: 8300691

Group type: EXPERIMENTAL
Intervention: Cephazolin (1 g single dose)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Cephazolin
Number of subjects: 141
Study: 2902683

Group type: EXPERIMENTAL
Intervention: Betaxolol (10 mg, intravenously)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol (15 mg, intravenously)
Number of subjects: 12
Study: 30626263

Group type: EXPERIMENTAL
Intervention: Local minocycline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 50
Study: 27085343

Group type: COMPARATOR
Intervention: Individuals with BMI <30 kg/m2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Individuals with BMI ≥30 kg/m2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Body Fat Percentage (BFP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Body Fat Mass (BFM)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 82
Study: 25616355

Group type: EXPERIMENTAL
Intervention: Sequential treatment (2.5 years of tamoxifen followed by 2.5 years of exemestane)
Number of subjects: 2596

Group type: COMPARATOR
Intervention: Exemestane treatment
Number of subjects: 2596
Study: 22976166

Group type: EXPERIMENTAL
Intervention: Postures during computer use
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Discrepancies in workstation setups and worker anthropometrics
Number of subjects: 74
Study: 22031888

Group type: EXPERIMENTAL
Intervention: random noise stimulation (tRNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: direct current stimulation (tDCS)
Number of subjects: 0
Study: 19226424

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo once daily for 2 years
Number of subjects: 0
Study: 16840878

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis (LRA) using 25 OCT parameters
Number of subjects: 160

Group type: COMPARATOR
Intervention: OCT-provided parameters
Number of subjects: 160
Study: 12757571

Group type: EXPERIMENTAL
Intervention: Activity program (low-resistance exercises and weight-shifting activities)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Education program (focused on identifying and reducing risk factors for falls)
Number of subjects: 38